Immuneering
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (IMRX)
- Website
- immuneering.com
- Company page
Recent activity at Immuneering
Immuneering funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Venture | $25.0M |
| Jan 2021 | Venture | $37.2M |
| Jan 2020 | Venture | $20.0M |
| Oct 2019 | Venture | $20.0M |
Leadership
- Joseph Kekst, Director
- Robert Carpenter, Director
- Benjamin Zeskind, Executive Officer, Director
- Robert Carpenter, Director
- Benjamin Zeskind, Executive Officer, Director
- Ben Zeskind, Founder
- Igor Matushansky, Chief Medical Officer
Verified email and direct lines for Immuneering’s decision-makers are on Fundz. See plans
Employee benefit plans
Immuneering files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Immuneering in the news
- Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - marketscreener.com (Oct 02, 2026)
- A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. - Stock Titan (Sep 24, 2026)
- Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference | IMRX Stock News - Quiver Quantitative (Sep 10, 2026)
- Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer - The Manila Times (Sep 28, 2026)
- Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes - BioSpace (May 18, 2026)
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - Yahoo Finance (Jan 07, 2026)
- First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer - OncLive (Sep 25, 2025)
- Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution - Fierce Biotech (Jan 08, 2026)
Companies similar to Immuneering
- Kinnate Biopharma · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Savara Inc · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Century Therapeutics, Inc. · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Elevation Oncology · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Inhibitor Therapeutics · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
About Immuneering: questions and answers
What does Immuneering do?
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d
Where is Immuneering headquartered?
Immuneering is headquartered in Cambridge, Massachusetts, United States.
Has Immuneering raised funding?
Yes. Fundz has recorded 4 funding events for Immuneering. The most recent, $25.0M, was in Sep 2025.
Who leads Immuneering?
Ben Zeskind is a Founder at Immuneering.
What is the latest news on Immuneering?
On Sep 09, 2025, Immuneering
Is Immuneering a public company?
Yes. Immuneering is publicly traded under the ticker IMRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy